Search research articles

Search research articles

Related Experiment Videos

Lipid disorders in type 2 diabetes.

¹Preventive Cardiology Center, Rush Heart Institute, and Associate Professor, Rush University College of Nursing, Chicago, Illinois 60612, USA.

The Nursing Clinics of North America

|May 31, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Asessing coronary heart disease risk and managing lipids.

The Nurse practitioner·2002

Same author

The accumulative effects of physical activity in hypertensive post-menopausal women.

Journal of cardiovascular risk·2001

Same author

The effects of crossed leg on blood pressure measurement.

Nursing research·1999

Same author

The influence of self-efficacy on exercise intensity, compliance rate and cardiac rehabilitation outcomes among coronary artery disease patients.

Progress in cardiovascular nursing·1997

Same author

Benefits of aerobic exercise after stroke.

Sports medicine (Auckland, N.Z.)·1996

Same author

Instrument development and measurement of exercise self-efficacy in cardiac rehabilitation patients.

Progress in cardiovascular nursing·1995

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Diabetes mellitus (DM) significantly increases cardiovascular disease (CVD) risk. Atherogenic dyslipidemia, common in type 2 DM, necessitates lipid screening and treatment to reduce morbidity and mortality.

Area of Science:

Endocrinology
Cardiology
Metabolic Syndrome

Background:

Diabetes mellitus (DM) is a primary risk factor for cardiovascular disease (CVD).
Type 2 DM, the most common form, elevates CVD morbidity and mortality risk by 2-3 fold.
Insulin resistance in type 2 DM is linked to a cluster of CVD risk factors, including dyslipidemia.

Purpose of the Study:

To discuss cardiovascular disease risk in patients with diabetes mellitus.
To characterize atherogenic dyslipidemia associated with DM.
To review lipid screening, clinical trial evidence, and treatment strategies for hyperlipidemia in DM.

Main Methods:

Literature review of studies on DM, CVD, dyslipidemia, and hyperlipidemia treatment.
Analysis of clinical trial data regarding lipid-lowering therapies.

Related Experiment Videos

Discussion of current treatment guidelines and approaches.

Main Results:

DM significantly elevates CVD risk, particularly type 2 DM.
Atherogenic dyslipidemia is a key component of the metabolic abnormalities in DM.
Evidence supports the efficacy of lipid-lowering treatments in reducing CVD events in diabetic patients.

Conclusions:

Managing dyslipidemia is crucial for reducing CVD risk in individuals with DM.
Comprehensive screening and tailored treatment approaches are essential.
Addressing insulin resistance and associated metabolic factors is key to cardiovascular risk reduction.